Piperazine, 1-(3-methyl-2-thienyl)- | 1121610-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Piperazine, 1-(3-methyl-2-thienyl)-
• 英文别名: 1-(3-methylthiophen-2-yl)piperazine
• CAS: 1121610-29-4
• 化学式: C₉H₁₄N₂S
• 分子量: 182.29
• InChiKey: OAOUUBBCPFEPGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  43.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS<br/>[FR] DERIVES DE PIPERAZINES 1-ARYL-4-SUSBTITUES UTILISES EN TANT QU'ANTAGONISTES DU CCR1 DANS LE TRAITEMENT DE L'INFLAMMATION ET DES TROUBLES IMMUNITAIRES
  申请人：CHEMOCENTRYX INC

  公开号：WO2003105853A1

  公开（公告）日：2003-12-24

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了作为CCR1受体强效拮抗剂的化合物，并且已经在动物炎症测试中进一步确认，炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基哌嗪衍生物，在制药组合物、治疗CCR1介导疾病的方法以及用于鉴定竞争性CCR1拮抗剂的检测中具有用途。
• Substituted piperazines
  申请人：ChemoCentryx, Inc.

  公开号：US20040162282A1

  公开（公告）日：2004-08-19

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了作为CCR1受体强效拮抗剂的化合物，并且这些化合物在动物炎症测试中进一步得到确认，炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基哌嗪衍生物，在制药组合物、治疗CCR1介导疾病的方法以及用作竞争性CCR1拮抗剂鉴定的检测中是有用的。
• SUBSTITUTED PIPERAZINES
  申请人：Pennell Andrew M.K.

  公开号：US20080261987A1

  公开（公告）日：2008-10-23

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了一种作为CCR1受体强效拮抗剂的化合物，已经在动物炎症测试中进一步确认，这是CCR1标志性疾病状态之一。这些化合物通常是芳基哌嗪衍生物，可用于制药组合物、治疗CCR1介导疾病的方法，以及用作竞争性CCR1拮抗剂鉴定的控制物。
• Arylpiperazinylalkoxy derivatives of cyclic imides, a process for their preparation and their use as medicaments
  申请人：HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED

  公开号：EP0333137A1

  公开（公告）日：1989-09-20

  There are disclosed compounds of the formula wherein the group A is where R₁ and R₂ are each independently hydrogen or loweralkyl, or R₁ + R₂ = (CH₂)m, m being 2 to 6, p is 1 or 2, and each X is independently hydrogen, loweralkyl, loweralkoxy, halogen, hydroxy, nitro, amino, loweralkylamino, diloweralkylamino, trifluoromethyl or loweralkylthio; W is O, H₂ or [H, OH]; n is 2, 3 or 4; and R₃ is where q is 1 or 2 and each Y is independently hydrogen, loweralkyl, loweralkoxy, halogen, hydroxy, nitro, amino, loweralkylamino, diloweralkylamino, trifluoromethyl or loweralkylthio, and a process for their preparation. The compounds of the present invention are useful as anti-­psychotic, anxiolytic or analgesic agents.

  公开了如下式的化合物 其中基团 A 为 其中 R₁ 和 R₂ 各自独立地为氢或低级烷基，或 R₁ + R₂ = (CH₂)m，m 为 2 至 6，p 为 1 或 2，且每个 X 独立地为氢、低级烷基、低级烷氧基、卤素、羟基、硝基、氨基、低级烷基氨基、稀释烷基氨基、三氟甲基或低级烷硫基；W 是 O、H₂ 或 [H，OH]； n 是 2、3 或 4；以及 R₃ 是 其中 q 是 1 或 2，每个 Y 独立地是氢、低级烷基、低级烷氧基、卤素、羟基、硝基、氨基、低级烷基氨基、稀释烷基氨基、三氟甲基或低级烷硫基，以及它们的制备方法。 本发明的化合物可用作抗精神病药、抗焦虑药或镇痛药。
• REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES
  申请人：Nippon Kayaku Kabushiki Kaisha

  公开号：EP0995741A1

  公开（公告）日：2000-04-26

  Remedies / preventives (therapeutic or preventive agents) against frequent urination (pollakiuria) / urinary incontinence which contain as an active ingredient compound having a tropone structure or pharmacologically acceptable salt thereof and a novel compound having the tropone structure. The compounds having a tropone structure and having the above pharmacological effects are those represented by, for example, general (1): wherein R1 and R2 represent each a hydrogen atom, lower alkyl group, etc., R3 represents -OR or -NR2 ; R4, R5 and R12 represents each a hydrogen atom or a lower alkyl group, X represents a nitrogen atom or CH, Z represents -CHAr2, an unsubstituted or substituted phenyl, etc. m is 1 or 2. These compounds are novel ones excluding those wherein Z is -CH Ar2.

  针对尿频（pollakiuria）/尿失禁的补救剂/预防剂（治疗剂或预防剂），其活性成分包含具有托品酮结构的化合物或其药理学上可接受的盐，以及具有托品酮结构的新型化合物。具有托品酮结构并具有上述药理作用的化合物是由例如通式（1）所代表的化合物： 其中 R1 和 R2 分别代表氢原子、低级烷基等，R3 代表-OR 或-NR2；R4、R5 和 R12 分别代表氢原子或低级烷基，X 代表氮原子或 CH，Z 代表-CHAr2、未取代或取代的苯基等，m 为 1 或 2。这些化合物均为新型化合物，不包括 Z 为-CH Ar2 的化合物。